In Legal

Follow this topic

Bookmark

Record learning outcomes

A lot has been written about the clinical benefits of the reforms but independent pharmacy owners should not overlook the legal and contractual implications, says Richard Hough…

The introduction of independent prescribing (IP) into NHS community pharmacy services is rightly being viewed as one of the most significant developments in the evolution of the sector.

Much of the discussion to date has understandably focused on the opportunities. IP has the potential to enhance access to care, reduce pressure on GP services and further establish community pharmacies as a core part of primary care delivery. However, while much has been written about the clinical benefits of the reforms, pharmacy owners should not overlook the legal and contractual implications.

In reality, IP is about far more than simply employing a pharmacist with an additional qualification; it has the potential to materially alter the risk profile of a pharmacy business and may require significant changes to governance arrangements, contracts and operational procedures.

Recent changes to the Community Pharmacy Contractual Framework (CPCF) arrangements for 2026/27 indicate that pharmacist independent prescribers (PIPs) will increasingly become embedded within NHS-funded services, including future developments of Pharmacy First and other clinical services.

For pharmacy owners, this means the legal position is beginning to shift. Historically, community pharmacies have primarily been viewed as providers of dispensing and supply services.

IP moves pharmacies further into the realm of direct clinical decision-making. That distinction is important. When a pharmacy dispenses a medicine which has been prescribed by another healthcare professional (HCP), as has historically been the case, responsibility for diagnosis and prescribing usually rests elsewhere, i.e. with the relevant HCP.

However, once a pharmacist is independently assessing, diagnosing and prescribing, the pharmacy assumes a more direct role in patient care. Inevitably, that creates new legal and regulatory considerations.

One area that is likely to require closer attention is clinical governance. Most pharmacy businesses already have robust standard operating procedures (SOPs), incident reporting systems and governance frameworks.

However, these arrangements have evolved predominantly around dispensing activities rather than prescribing services. As prescribing becomes more commonplace within community pharmacies, owners should consider whether their existing SOPs require updatiing or remain fit for purpose.

New prescribing pathways may require revised governance documents, enhanced clinical audit programmes, additional quality assurance measures and clear escalation procedures for complex clinical situations.

Superintendent pharmacists are also likely to find themselves exercising greater oversight of prescribing arrangements across their organisations. Liability is another area that deserves careful consideration. Dispensing errors have long represented a key area of risk within community pharmacy.

Prescribing introduces additional risk exposure. Allegations may arise not only from supply errors but also from clinical decision-making itself, such as misdiagnosis, inappropriate prescribing, failure to identify contraindications or failures to refer patients for further medical assessment.

As a result, pharmacy owners should carefully review professional indemnity arrangements and ensure that their insurance cover remains appropriate for the scope of services being provided.

It would also be prudent to consider whether employment contracts and locum agreements adequately address prescribing responsibilities and allocate liability appropriately. The workforce implications should not be underestimated either. For many businesses, PIPs may become a strategically important asset. Recruitment, retention and training are therefore likely to assume greater commercial significance.

Employment documentation may increasingly include provisions relating to maintenance of prescribing qualifications, prescribing-specific continuing professional development requirements, compliance with service specifications and participation in clinical governance processes.

The contractual position becomes even more complex where pharmacies operate alongside digital health providers or online prescribing platforms.

Many pharmacy businesses now work closely with technology providers, telemedicine services and remote prescribing organisations. In those arrangements, clear contractual delineation of responsibility is essential. Who is responsible for assessing the patient? Who is responsible for the prescribing decision? Who is responsible for monitoring outcomes and managing complaints?

Historically, some agreements may have assumed a relatively straightforward dispensing role for the pharmacy. IP adoption by the pharmacy may require a fundamental review of those arrangements. Areas such as clinical governance, data sharing, audit rights, indemnities and dispute resolution provisions are likely to assume greater importance.

Owners should also keep a close eye on the wider regulatory environment. The General Pharmaceutical Council, Care Quality Commission and NHS England have all demonstrated an increasing willingness to scrutinise remote prescribing models and clinical decision-making processes, particularly in relation to higher-risk medicines and online healthcare services.

IP is likely to attract a similar level of regulatory scrutiny. Those pharmacies that can demonstrate robust governance and clear accountability structures are likely to be best placed to manage that scrutiny.

There are implications for pharmacy transactions as well. As IP becomes more integrated into NHS and private service delivery, prescribing capability may increasingly form part of business valuations and due diligence exercises. Purchasers and investors may want to understand how many PIPs are employed within a business, what governance arrangements are in place and whether any prescribing-related incidents or claims have arisen historically.

Consequently, sale and purchase agreements may begin to include more detailed warranties and indemnities relating to prescribing activity, clinical governance and regulatory compliance. None of this should be seen as a reason to resist change. Quite the opposite. IP potentially represents one of the most significant opportunities for community pharmacy in decades.

It supports the long-term transition from a dispensing-led model towards a clinically focused healthcare service that is embedded within primary care pathways. Nevertheless, pharmacy owners should recognise that the benefits come with additional responsibilities. In many respects, the most important consequence of IP may not be the prescribing right itself.

Rather, it is the transformation of community pharmacy into a more clinically accountable healthcare provider. That transformation will require not only investment in people and training, but also careful attention to contracts, governance and risk management.

Those businesses that prepare early are likely to be best positioned to take most advantage of the opportunities that IP will bring while managing the legal and regulatory risks that inevitably accompany such a significant change.

Richard Hough is a partner and head of healthcare at Brabners and a former pharmacist.